Genomic biomarkers
in metastatic
colorectal cancer

In this focus on genomic biomarkers in mCRC, VJOncology delivers updates from ASCO & ESMO WCGIC 2023 on…

  The current standard practice for biomarker testing

  The challenges and barriers to biomarker testing

  Potential treatment directions in the future

MOUNTAINEER: genomic alterations on tucatinib plus trastuzumab activity

John Strickler, MD
Duke Cancer Center, Durham, NC

CRC predicative biomarkers in guiding treatment decisions

Kristen Ciombor, MD, MSCI
Vanderbilt-Ingram Cancer Center, Nashville, TN

GALAXY: ctDNA as a prognostic biomarker in resected CRC

Yoshiaki Nakamura, MD, PhD,
National Cancer Center Hospital East, Kashiwa, Japan

The potential future of genomic biomarker testing and treatment in mCRC

Progress made in targeting KRAS in GI malignancies

Benedikt Westphalen, MD
LMU Hospital, Munich, Germany

Targeting less common mutations
in colorectal cancer

Sebastian Stintzing, MD
Charite University Hospital, Berlin, Germany

CodeBreaK 300: Sotorasib for KRAS G12C-mutated CRC

Filippo Pietrantonio, MD
Istituto Nazionale dei Tumori, Milan, Italy

Testing recommendations of predictive genomic biomarkers in mCRC

*NGS panels used may enable rare alterations to be picked up, i.e. NTRK
**Emerging biomarkers include HER2, MET, KRAS gene amplification, TGFα, EGFR mutations, and alterations in HER3, PI3KCA, and PTEN
±NTRK and HER2 are recommended for testing at relapse

MSI, microsatellite instability; MMR, mismatch repair; NGS, Next generation sequencing; NTRK, neurotrophic tyrosine receptor kinase fusions

Find out more on these biomarkers below:

Coming soon…

Check out VJOncology for future updates on this topic, including…

     Updates from clinical trials and other targeted biomarkers in mCRC

     Biomarker focus: Genetic mutations in HER2, BRAF V600E, MEK, NTRK and KRAS G12C

    Improving access to biomarker testing in mCRC and incorporating increased testing into clinical practice



Benson AB, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021 Mar 2;19(3):329–359. Colorectal Cancer: Statistics. Available at: Accessed: November 2022. Last Updated: May 2022.

Colorectal cancer NICE guideline [NG151]. Available at: Published January 2020. Last updated 15 December 2021.

Puccini A, et al. Biomarkers in metastatic colorectal cancer: status quo and future perspective. Cancers (Basel) 2022 Oct 3;14(19):4828.

Rachiglio AM, et al. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Explor Target Antitumor Ther 2020;1(1):53–70.

Sepulveda A, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Oncol Pract 2017;13(5):333–337.

Van Custem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8):1386–422.

Yu I, et al. Tumor biomarker testing for metastatic colorectal cancer: a Canadian consensus practice guideline. Ther Adv Med Oncol 2022;14:17588359221111705.

This educational activity has been supported by medical education support from Seagen.
This supporter has no influence over the production of the content.